CASE REPORT: Cefazolin-induced Hemolytic Anemia

Cerynik, Douglas L.; Lee, Gwo-Chin; Fayssoux, Reginald S.; Amin, Nirav H.

doi:10.1097/blo.0b013e31803d3aad

Cited by 5 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cerynik et al reported a case of a 50-year-old man with hemolytic anemia secondary to cefazolin administration for right total knee arthroplasty [ 4 ]. Prophylactic cephalosporin was administered and postoperatively, IV cefazolin was continued, with anemia developing postoperative day 1.…”

Section: Resultsmentioning

confidence: 99%

“…However, to our knowledge, a negative DAT does not definitively rule out DIIHA, because there are several drug-induced immune hemolytic anemia mechanisms [ 7 ]. First, the drug can act as a hapten—where antibodies are only detected in the presence of the drug [ 1 , 4 , 8 ]. Second, the drug can elicit an immune response mediated by autoantibodies—antibodies are drug-independent.…”

Section: Conclusion and Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cefazolin-induced hemolytic anemia: a case report and systematic review of literature

2021

View full text Add to dashboard Cite

Background Cefazolin is a first-generation cephalosporin commonly used for skin and soft tissue infections, abdominal and orthopedic surgery prophylaxis, and methicillin-sensitive staph aureus. Cephalosporins as a whole are known potential inducers of hemolytic anemia; however, mechanism of action is primarily autoimmune, and compared to other drugs, cefazolin is the least common. Methods A rare case report of cefazolin-induced hemolytic anemia “CIHA” and a systematic review of CIHA articles in English literature. Two authors performed review of publications and articles were selected based on inclusion and exclusion criteria. A systematic search of the literature yielded 768 entries with five case reports on cefazolin-induced hemolytic anemia. Case presentation/results An 80-year-old female with methicillin-sensitive Staphylococcus aureus “MSSA” endocarditis. The patient was started on intravenous “IV” cefazolin that that resulted in hemolytic anemia and eosinophilia. Switching to vancomycin improved hemoglobin level and resolved eosinophilia. Four cefazolin-induced hemolytic anemia case reports and one population-based article with a case reported were analyzed with respect to direct antiglobulin test “DAT” (also known as the direct Coombs test) results, prior penicillin sensitivity, and acute anemia causes exclusion. Conclusions CIHA is a rare cause of clinically significant anemia. The diagnosis of drug-induced anemia is one of exclusion. It is important to consider DAT results and prior penicillin sensitivity when evaluating a patient for cefazolin-induced hemolytic anemia. However, the frequency of cefazolin use and resultant anemia necessitates early recognition of hemolytic anemia and prompt discontinuation of cefazolin, especially with long-term use.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Conclusion and Discussionmentioning

confidence: 99%

Cefazolin-induced hemolytic anemia: a case report and systematic review of literature

2021

View full text Add to dashboard Cite

show abstract

“…Neither medication was taken by our patient; however, about 6 weeks earlier he had been on a cephalosporin for 5 days. Indeed, cephalosporins are known to be potential inducers of clinically significant hemolytic anemia [ 27 – 30 ].…”

Section: Differential Diagnosismentioning

confidence: 99%

Clinical-Pathological Conference Series from the Medical University of Graz

Fabian

Stadlbauer

Keil

et al. 2022

Wien Klin Wochenschr

View full text Add to dashboard Cite

Current awareness: Pharmacoepidemiology and drug safety

2008

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

CASE REPORT: Cefazolin-induced Hemolytic Anemia

Cited by 5 publications

References 15 publications

Cefazolin-induced hemolytic anemia: a case report and systematic review of literature

Cefazolin-induced hemolytic anemia: a case report and systematic review of literature

Clinical-Pathological Conference Series from the Medical University of Graz

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About